Full-Time

Professional Sales Representative

Posted on 5/17/2025

Amplity

Amplity

1-10 employees

Database of de-identified medical records

No salary listed

Junior

Lexington, KY, USA

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Marketing
Requirements
  • Bachelor’s Degree (BA/BS) required; life science major preferred but not required
  • 1 year or more Successful outside sales experience; life science industry preferred but not required - Required
  • Strong communication and presentation skills - Intermediate
Responsibilities
  • Achieve all product sales performance goals and objectives for geographical assignment (Territory). Distribute samples and record sample transactions in accordance with Company Policy and PDMA guidelines.
  • Develop comprehensive and accurate sales presentations using all approved marketing and selling materials.
  • Maintain proficient knowledge of promoted product disease states and indications.
  • Deliver proficient sales presentations to a defined list of current and prospective customers with a frequency based on assigned call goals.
  • Implement the selling model and process principles, including the DiSC personality profile when engaging with customers.
  • Complete pre and post call analysis which positively impacts customer interactions.
  • Regularly review and analyze all available sales data and utilize developmental budget funds.
  • Adhere to all compliance policies and guidelines.
  • Develop a daily call schedule to insure efficient and comprehensive coverage of territory.
  • Complete administrative reports and meet related deadlines.
  • Ensure proper safeguarding and care for company assets (laptop, iPad, fleet vehicle. etc.).
  • Maintain a call average of 8 or more calls per day, 40 or more calls per week, defined as face-to-face interactions, with healthcare providers focusing on top target customers.
  • Enter calls immediately into Veeva System via iPad and check/respond to email daily.
Desired Qualifications
  • life science major preferred but not required
  • life science industry preferred but not required

Amplity focuses on transforming medical records into actionable data for healthcare providers and researchers. The company compiles de-identified medical records into a comprehensive database that can be searched for various elements such as diseases, medications, and devices. This database includes millions of records from diverse specialties across all 50 states, allowing users to gain insights into patient conditions and their interactions with healthcare professionals. Unlike many competitors, Amplity emphasizes providing customized access to real-world healthcare outcomes, aiming to enhance decision-making in clinical settings.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$102.5M

Headquarters

Santa Cruz, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Amplity's AI-driven platform offers real-time insights for pharmaceutical leaders.
  • The merger with Lynx could expand Amplity's capabilities in medical communications.
  • Amplity's leadership change aims to increase visibility in the biopharmaceutical market.

What critics are saying

  • Rapid AI advancements could outpace Amplity's current healthcare analytics offerings.
  • Integration challenges from the Lynx merger may disrupt service delivery.
  • Data privacy regulations could limit Amplity's access to real-world data insights.

What makes Amplity unique

  • Amplity leverages AI-driven platforms for actionable insights during drug launch windows.
  • Their proprietary database, Amplity Insights, analyzes over 70 million electronic medical records.
  • Amplity's real-world data solutions enhance understanding of clinical decision-making in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Company News

Amplity
May 15th, 2025
Amplity Unveils GLP-1 RAs & Biologic Trends At ISPOR 2025

Amplity unveils GLP-1 RAs & biologic trends at ISPOR 2025.

PR Newswire
Jun 7th, 2024
Amplity Health Study Identifies Major Gaps In Biomarker Testing And Targeted Therapy Use In Non-Small Cell Lung Cancer In The United States

Research presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting shows how the Amplity Health Insights™ Real-World Database enhances understanding of clinical decision-makingLANGHORNE, Pa., June 7, 2024 /PRNewswire/ -- Using point-of-care real-world data to analyze patterns, Amplity Health, a contract sales and medical outsourcing partner, found that biomarker testing for patients with non-small cell lung cancer (NSCLC) in the United States is significantly underutilized. Presented on June 3 at the 2024 ASCO Annual Meeting in Chicago, "Biomarker Testing and Targeted Therapy Use Among Patients With Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database," highlights critical gaps in testing practices and underscores the need for improved diagnostic strategies.Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study, shares “Biomarker Testing and Targeted Therapy Use Among Patients with Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database,” at #ASCO24.By using natural language processing to examine more than 70 million records, this study showed that:A total of 61,018 patients were identified in the Amplity Health Insights ™ Database as having been diagnosed with NSCLC from October 2003 through November 2023™ Database as having been diagnosed with NSCLC from through Of the patients identified in the database as having NSCLC, only 13.4% were recorded as being biomarker testedOf the 6,387 patients with a mutation identified, only approximately 36% received an indicated treatment"Our data further suggest that even when biomarker testing is conducted, and actionable mutations are confirmed, many patients may not be receiving an appropriate targeted therapy," says Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study."When working with healthcare providers and clients, Amplity's goal is to help remove barriers and address social determinants related to biomarker testing and treatment, ultimately enhancing outcomes across all populations," adds Chris Baker, CEO of Amplity Health.Insights, Amplity's proprietary real-world qualitative database, analyzes over 70 million electronic medical records and effectively uncovers gaps in care. By leveraging data from community settings, combined with ethnicity and SDOH variables, Insights can be used to identify and address social inequities in healthcare. This enables pharmaceutical organizations to better align their strategies to ensure inclusive treatment and access for all patients.About Amplity InsightsAmplity Insights is Amplity Health's proprietary data offering, which provides solutions to clients' most elusive data challenges. By illuminating WHY healthcare practitioners make treatment decisions, our data solutions assist health economics and outcomes research, commercial, clinical, and data analytics teams in biopharma to rapidly move from hypothesis to impact. The mission of Amplity Insights is to maximize the utility of unstructured data by creating easy-to-use, state-of-the-art products and tools to empower leaders to serve patients better.This includes an unparalleled database, the Xplore platform, and the AI-driven search tool, AskX

S&P Global
Feb 21st, 2024
Amplity Health nets $102.5M incremental loan

Earlier this month, Amplity Health announced a merger with medical communications company Lynx.

PR Newswire
Feb 5th, 2024
Amplity Health Announces Leadership Changes

LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role

PR Newswire
Feb 5th, 2024
Amplity Health Announces Leadership Changes Usa - English

LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role